National
Desk
| June 2, 2003, Monday New Tacks
in Cancer Treatment Show Promise in 2
Clinical Trials
By ANDREW POLLACK (NYT) 1559 words
Late Edition - Final , Section A ,
Page 1 , Column 1
ABSTRACT
- Two experimental drugs that fight cancer
in novel ways succeed in clinical trials,
ending lingering doubts about their
effectiveness and promising new era in
treatment of disease; new drugs are products
of biotechnology that attack particular
mechanism by which cancer cells grow; they
promise to extend by months lives of those
who contract it or to shrink tumors, while
avoiding some of serious side effects of
conventional chemotherapy; they open door to
further research that may yield wave of even
more effective drugs operating on similar
lines; one drug, Avastin, developed by
Genentech, allowed patients with advanced
colorectal cancer to live nearly five months
longer; other drug is Erbitux, also tested
on advanced colorectal cancer patients; it
was developed by ImClone Systems, company
dogged by scandal; its first application for
approval of drug was rejected in 2001
because Food and Drug Adm said company's
clinical trials were poorly designed and
sloppily conducted; results of more
carefully conducted trial are almost
identical to those of pervious study,
potentially clearing way for approval of
drug; photo (M) Two experimental drugs that
fight cancer in novel ways have succeeded in
clinical trials, ending lingering doubts
about their effectiveness and promising a
new era in the treatment of the disease,
doctors said here today.
The two new drugs, products of
biotechnology, each attack a particular
mechanism by which cancer cells grow.
PURCHASING
FROM NYTIMES.COM IS QUICK AND
SECURE.
To read the complete article,
simply click on one of the BUY
NOW buttons below.
You can buy
this single article or, for even
greater value, you can purchase
this article as part of a
multi-pack. You'll then have the
opportunity to buy additional
articles now or in the future at
significant savings!
Purchase
Single Article -- $2.95
Purchase as part of Article
4-Pack -- $7.95 ($1.99/article - a 33%
savings!)
Pack expires after 1 month
Purchase as part of Article
10-Pack -- $15.95 ($1.60/ article - a 46%
savings!)
Pack expires after 3 months
Purchase as part of Article
25-Pack -- $25.95 ($1.05/ article - a 65%
savings!)
Pack expires after 6 months
How multi-packs work: A
multi-pack is an archive package that saves
you money by allowing you to pre-purchase a
set number of articles in bulk at a reduced
price. You can then debit from your
multi-pack and quickly access articles from
the archive at your convenience over the
lifetime of the multi-pack.
Once you purchase an
article, you may view it as often as you
like over the next 90 days. Archive articles
do not include photos, charts or graphics
DISCLAIMER: All
information, data, and material contained, presented, or provided here is for
general information purposes only and is not to be construed as reflecting the
knowledge or opinions of the publisher, and is not to be construed or intended
as providing medical or legal advice. The decision whether or not to vaccinate
is an important and complex issue and should be made by you, and you alone, in
consultation with your health care provider.
"A foolish faith in authority is the worst enemy of truth."
-- Albert Einstein, letter to a friend, 1901
"I know of no safe depository of the ultimate powers of the society but the people themselves, and if we think them not enlightened enough to exercise control with a wholesome discretion, the remedy is not to take it from them, but to inform their discretion by education."
-- Thomas Jefferson, letter to William C. Jarvis, September 28, 1820
"What's the point of vaccination if it doesn't protect you from the unvaccinated?"
-- Sandy Gottstein
"Who gets to decide what the greater good is and how many will be sacrificed to it?"